Amit C. Nathwani, M kamagra .B., Ch.B., Ph.D., Edward G.D. Tuddenham, M.B., B.S., M.D., Savita Rangarajan, M.B., B.S., Cecilia Rosales, Ph.D., Jenny McIntosh, Ph.D., David C. Linch, M.B., B.Chir., Pratima Chowdary, M.B., B.S., Anne Riddell, B.Sc., Arnulfo Jaquilmac Pie, B.S.N., Chris Harrington, B.S.N., James O’Beirne, M.B., B.S., M.D., Keith Smith, M.Sc., John Pasi, M.D., Bertil Glader, M.D., Ph.D., Pradip Rustagi, M.D., Catherine Y.C. Ng, M.S., Tag A. Kay, M.D., Ph.D., Junfang Zhou, M.D., Yunyu Spence, Ph.D., Christopher L. Morton, B.S., James Allay, Ph.D., John Coleman, M.S., Susan Rest, Ph.D., John M.

Patients were then followed every 6 months to the finish of the study. Study Outcomes For the portion of the scholarly study where the prognostic value of subclinical atrial fibrillation was evaluated, the principal outcome was ischemic stroke or systemic embolism. Secondary outcomes were vascular death, myocardial infarction, stroke from any cause, and atrial tachyarrhythmias documented by surface electrocardiography. The definitions of the individual outcome events are provided in the Supplementary Appendix. All the available device electrograms that demonstrated subclinical atrial tachyarrhythmias, as well as all clinical occasions, were at the mercy of blinded adjudication by professional committees. The principal outcome of the randomized trial of continuous atrial overdrive pacing was symptomatic or asymptomatic atrial tachyarrhythmia lasting more than 6 minutes, documented by surface area electrocardiographic recording.19 The total results of this randomized comparison are presented only briefly in this report, since this report is intended to target primarily on the findings of the observational study of the prognostic value of subclinical atrial fibrillation.